You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMestranol
Accession NumberDB01357
TypeSmall Molecule
GroupsApproved
DescriptionThe 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
NeconWatson Pharma, Inc.
NorinylActavis Pharma, Inc.
Norinyl 1/50 -(21-day Regimen)Pfizer Canada Inc
Norinyl 1/50 -(28-day Regimen)Pfizer Canada Inc
Norinyl 1/50 21 TabSyntex Inc.
Norinyl 1/50 28 TabSyntex Inc.
Ortho-novum 1/50 Tablets (21 Day)Janssen Inc
Ortho-novum 1/50 Tablets (28 Day)Janssen Inc
SaltsNot Available
Categories
UNIIB2V233XGE7
CAS number72-33-3
WeightAverage: 310.4299
Monoisotopic: 310.193280076
Chemical FormulaC21H26O2
InChI KeyInChIKey=IMSSROKUHAOUJS-ZTUUXWJNNA-N
InChI
InChI=1/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/s2
IUPAC Name
(1S,10R,11S,14R,15S)-14-ethynyl-5-methoxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-14-ol
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrane steroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Hydroxysteroid
  • Estrane-skeleton
  • Phenanthrene
  • Tetralin
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Ynone
  • Tertiary alcohol
  • Cyclic alcohol
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationMestranol was used as one of the first oral contraceptives.
PharmacodynamicsNot Available
Mechanism of actionMestranol is the 3-methyl ether of ethinylestradiol. Ethinylestradiol, is a synthetic derivative of estradiol. Ethinylestradiol is orally bio-active and the estrogen used in almost all modern formulations of combined oral contraceptive pills. It binds to (and activates) the estrogen receptor. Mestranol is a biologically inactive prodrug of ethinylestradiol to which it is demethylated in the liver with a conversion efficiency of 70%. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Mestranol
17β-ethinylestradiolDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9929
Blood Brain Barrier+0.9465
Caco-2 permeable+0.8463
P-glycoprotein substrateSubstrate0.656
P-glycoprotein inhibitor INon-inhibitor0.6099
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8148
CYP450 2C9 substrateNon-substrate0.7521
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7656
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9334
CYP450 2C19 inhibitorInhibitor0.7721
CYP450 3A4 inhibitorInhibitor0.5232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7758
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8714
BiodegradationNot ready biodegradable0.9829
Rat acute toxicity1.5234 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8958
hERG inhibition (predictor II)Inhibitor0.5679
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point150.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.00377 mg/mLALOGPS
logP3.89ALOGPS
logP4.04ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)17.59ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.46 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity91.86 m3·mol-1ChemAxon
Polarizability36.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.65 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-01t9-1972000000-5e394201ba0e38e5391fView in MoNA
1D NMR13C NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Mestranol.
AbciximabMestranol may decrease the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Mestranol can be decreased when combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Mestranol.
AcenocoumarolMestranol may decrease the anticoagulant activities of Acenocoumarol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Mestranol.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Mestranol.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Mestranol.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Mestranol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Mestranol.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Mestranol.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Mestranol.
AmiodaroneThe metabolism of Mestranol can be decreased when combined with Amiodarone.
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Mestranol.
AncrodMestranol may decrease the anticoagulant activities of Ancrod.
Anthrax immune globulin humanMestranol may increase the thrombogenic activities of Anthrax immune globulin human.
Antithrombin III humanMestranol may decrease the anticoagulant activities of Antithrombin III human.
ApixabanMestranol may decrease the anticoagulant activities of Apixaban.
AprepitantThe metabolism of Mestranol can be increased when combined with Aprepitant.
ArdeparinMestranol may decrease the anticoagulant activities of Ardeparin.
ArgatrobanMestranol may decrease the anticoagulant activities of Argatroban.
BecaplerminMestranol may decrease the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Mestranol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Mestranol.
BivalirudinMestranol may decrease the anticoagulant activities of Bivalirudin.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Mestranol.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Mestranol.
C1 Esterase Inhibitor (Human)Mestranol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Mestranol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Mestranol.
CapecitabineThe metabolism of Mestranol can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Mestranol can be increased when combined with Carbamazepine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Mestranol.
CeritinibThe serum concentration of Mestranol can be increased when it is combined with Ceritinib.
CertoparinMestranol may decrease the anticoagulant activities of Certoparin.
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Mestranol.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Mestranol.
CholecalciferolThe metabolism of Mestranol can be decreased when combined with Cholecalciferol.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Mestranol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Mestranol.
Citric AcidMestranol may decrease the anticoagulant activities of Citric Acid.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Mestranol.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Mestranol.
ClotrimazoleThe metabolism of Mestranol can be decreased when combined with Clotrimazole.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Mestranol.
CyclosporineThe metabolism of Mestranol can be decreased when combined with Cyclosporine.
Dabigatran etexilateMestranol may decrease the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Mestranol can be decreased when it is combined with Dabrafenib.
DalteparinMestranol may decrease the anticoagulant activities of Dalteparin.
DanaparoidMestranol may decrease the anticoagulant activities of Danaparoid.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Mestranol.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Mestranol.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Mestranol.
DelavirdineThe metabolism of Mestranol can be decreased when combined with Delavirdine.
DesirudinMestranol may decrease the anticoagulant activities of Desirudin.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Mestranol.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Mestranol.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Mestranol.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Mestranol.
DextranMestranol may decrease the anticoagulant activities of Dextran.
Dextran 40Mestranol may decrease the anticoagulant activities of Dextran 40.
Dextran 70Mestranol may decrease the anticoagulant activities of Dextran 70.
Dextran 75Mestranol may decrease the anticoagulant activities of Dextran 75.
DicoumarolMestranol may decrease the anticoagulant activities of Dicoumarol.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Mestranol.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Mestranol.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Mestranol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Mestranol.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Mestranol.
Edetic AcidMestranol may decrease the anticoagulant activities of Edetic Acid.
EdoxabanMestranol may decrease the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Mestranol can be decreased when combined with Efavirenz.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Mestranol.
EnoxaparinMestranol may decrease the anticoagulant activities of Enoxaparin.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Mestranol.
EquilinThe serum concentration of Equilin can be increased when it is combined with Mestranol.
EstroneThe serum concentration of Estrone can be increased when it is combined with Mestranol.
Ethyl biscoumacetateMestranol may decrease the anticoagulant activities of Ethyl biscoumacetate.
EtravirineThe metabolism of Mestranol can be decreased when combined with Etravirine.
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Mestranol.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Mestranol.
FloxuridineThe metabolism of Mestranol can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Mestranol can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Mestranol.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Mestranol.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Mestranol.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Mestranol.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Mestranol.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Mestranol.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Mestranol.
FluorouracilThe metabolism of Mestranol can be decreased when combined with Fluorouracil.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Mestranol.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Mestranol.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Mestranol.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Mestranol.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Mestranol.
FluvastatinThe metabolism of Mestranol can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Mestranol can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumMestranol may decrease the anticoagulant activities of Fondaparinux sodium.
FosphenytoinThe metabolism of Mestranol can be increased when combined with Fosphenytoin.
GemfibrozilThe metabolism of Mestranol can be decreased when combined with Gemfibrozil.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Mestranol.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Mestranol.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Mestranol.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Mestranol.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Mestranol.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Mestranol.
HeparinMestranol may decrease the anticoagulant activities of Heparin.
HirulogMestranol may decrease the anticoagulant activities of Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mestranol.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mestranol.
IndinavirThe metabolism of Mestranol can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Mestranol.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Mestranol.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Mestranol.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Mestranol.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Mestranol.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Mestranol.
IrbesartanThe metabolism of Mestranol can be decreased when combined with Irbesartan.
KetoconazoleThe metabolism of Mestranol can be decreased when combined with Ketoconazole.
LeflunomideThe metabolism of Mestranol can be decreased when combined with Leflunomide.
LenalidomideMestranol may increase the thrombogenic activities of Lenalidomide.
LepirudinMestranol may decrease the anticoagulant activities of Lepirudin.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Mestranol.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Mestranol.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Mestranol.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Mestranol.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Mestranol.
LosartanThe metabolism of Mestranol can be decreased when combined with Losartan.
LovastatinThe metabolism of Mestranol can be decreased when combined with Lovastatin.
LumacaftorThe serum concentration of Mestranol can be decreased when it is combined with Lumacaftor.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Mestranol.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Mestranol.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Mestranol.
MifepristoneThe serum concentration of Mestranol can be increased when it is combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Mestranol.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Mestranol.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Mestranol.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Mestranol.
NadroparinMestranol may decrease the anticoagulant activities of Nadroparin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Mestranol.
NicardipineThe metabolism of Mestranol can be decreased when combined with Nicardipine.
OmeprazoleThe metabolism of Mestranol can be decreased when combined with Omeprazole.
OspemifeneThe risk or severity of adverse effects can be increased when Mestranol is combined with Ospemifene.
OtamixabanMestranol may decrease the anticoagulant activities of Otamixaban.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Mestranol.
Pentosan PolysulfateMestranol may decrease the anticoagulant activities of Pentosan Polysulfate.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Mestranol.
PhenindioneMestranol may decrease the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Mestranol can be increased when combined with Phenobarbital.
PhenprocoumonMestranol may decrease the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Mestranol can be increased when combined with Phenytoin.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Mestranol.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Mestranol.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Mestranol.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Mestranol.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Mestranol.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Mestranol.
PrimidoneThe metabolism of Mestranol can be increased when combined with Primidone.
Protein CMestranol may decrease the anticoagulant activities of Protein C.
ProtocatechualdehydeMestranol may decrease the anticoagulant activities of Protocatechualdehyde.
PyrimethamineThe metabolism of Mestranol can be decreased when combined with Pyrimethamine.
QuinineThe metabolism of Mestranol can be decreased when combined with Quinine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Mestranol.
ReviparinMestranol may decrease the anticoagulant activities of Reviparin.
RifampicinThe metabolism of Mestranol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Mestranol can be increased when combined with Rifapentine.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Mestranol.
RivaroxabanMestranol may decrease the anticoagulant activities of Rivaroxaban.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Mestranol.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Mestranol.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Mestranol.
SecobarbitalThe metabolism of Mestranol can be increased when combined with Secobarbital.
SildenafilThe metabolism of Mestranol can be decreased when combined with Sildenafil.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Mestranol.
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Mestranol.
SorafenibThe metabolism of Mestranol can be decreased when combined with Sorafenib.
SulfadiazineThe metabolism of Mestranol can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Mestranol can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Mestranol can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Mestranol.
ThalidomideMestranol may increase the thrombogenic activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Mestranol.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Mestranol.
TicagrelorThe metabolism of Mestranol can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Mestranol can be decreased when combined with Ticlopidine.
TipranavirMestranol may increase the dermatologic adverse activities of Tipranavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Mestranol.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Mestranol.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Mestranol.
TolbutamideThe metabolism of Mestranol can be decreased when combined with Tolbutamide.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Mestranol.
TrimethoprimThe metabolism of Mestranol can be decreased when combined with Trimethoprim.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Mestranol.
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Mestranol.
Valproic AcidThe metabolism of Mestranol can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Mestranol can be decreased when combined with Valsartan.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Mestranol.
Vitamin CThe serum concentration of Mestranol can be increased when it is combined with Vitamin C.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Mestranol.
VoriconazoleThe metabolism of Mestranol can be decreased when combined with Voriconazole.
WarfarinMestranol may decrease the anticoagulant activities of Warfarin.
XimelagatranMestranol may decrease the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Mestranol can be decreased when combined with Zafirlukast.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Dulos J, Vijn P, van Doorn C, Hofstra CL, Veening-Griffioen D, de Graaf J, Dijcks FA, Boots AM: Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. Arthritis Res Ther. 2010;12(3):R101. doi: 10.1186/ar3032. Epub 2010 May 24. [PubMed:20497523 ]
  2. Cleuren AC, Van der Linden IK, De Visser YP, Wagenaar GT, Reitsma PH, Van Vlijmen BJ: 17alpha-Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor alpha. J Thromb Haemost. 2010 Aug;8(8):1838-46. doi: 10.1111/j.1538-7836.2010.03930.x. Epub 2010 May 27. [PubMed:20524981 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Vena R, Friedman HL, Shader RI: Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. J Clin Pharmacol. 1997 Mar;37(3):193-200. [PubMed:9089421 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:51 / Updated on August 17, 2016 12:23